NIH to review request to lower cancer drug's cost; Mirati's KRAS-blocking lung cancer drug clears safety hurdle

One year after being asked to widen access to a pricey cancer treatment, the NIH is only now preparing to review and assess the request. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by      STAT+: A year after petition, NIH will finally review request to lower cancer drug's cost by sidestepping patents By Ed Silverman Adobe “A rejection of the petition will encourage more aggressive pricing of drugs," wrote two cancer patients to the HHS. Read More STAT+: Mirati's KRAS-blocking lung cancer drug clears safety hurdle in combination study By Adam Feuerstein Andy Wong/AP Mirati's cancer drug adagrasib combined with another immunotherapy was well-tolerated by patients with lung cancer in a mid-stage study. Read More Sponsored Insight by Myriad Genetics Breast cancer risk: How genetic testing can support the continuum of care Approximately 13% of women in the United States will develop breast cancer in their lifetime1. That's one in eight women. We have an opportunity to advance the healthcare system to one that is driven by knowing risk and getting ahead of disease before it may even happen. Let's break down barriers and increase the adoption of genetic testing across the continuum of care to improve health outcomes for patients in breast cancer — and ultimately, many other cancers. Learn more. 1. Breastcancer.org, Breast Cancer Facts and Statistics,  https://www.breastcancer.org/facts-statistics Opinion: Better lab test standards can ensure precision medicine is truly precise By Jeff Allen and Lisa Lacasse SAUL LOEB/AFP/Getty Images The oversight of lab tests for targeted cancer therapies and other treatments has not kept pace with innovation. Read More Tuesday, December 6, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser